Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8737363 | Diagnostic Microbiology and Infectious Disease | 2018 | 17 Pages |
Abstract
The in vitro antimicrobial activity of iclaprim, a novel diaminopyrimidine, against common respiratory bacteria remained unchanged in the presence of pulmonary surfactant (Survanta®) at concentrations that greatly antagonized the antimicrobial activity of daptomycin. These results indicate that iclaprim could be a potential treatment for pneumonia caused by susceptible and multidrug resistant bacteria.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
David B. Huang, Leonard R. Duncan, Robert K. Flamm, Matthew Dryden, G. Ralph Corey, Mark H. Wilcox, Antoni Torres, Thomas M. Jr,